Quint, Jennifer K. http://orcid.org/0000-0003-0149-4869
Ariel, Amnon http://orcid.org/0000-0001-9266-7344
Barnes, Peter J. http://orcid.org/0000-0002-5122-4018
Funding for this research was provided by:
Boehringer Ingelheim (N/A, N/A, N/A)
Article History
Received: 10 January 2023
Accepted: 4 July 2023
First Online: 24 July 2023
Competing interests
: J.K.Q. declares personal fees for advisory board participation or speaking fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Chiesi, but declares no non-financial competing interests. A.A. declares personal fees from AstraZeneca, and personal fees and non-financial support from Boehringer Ingelheim, outside the submitted work. P.J.B. declares research funding from AstraZeneca and Boehringer Ingelheim; consulting fees from AstraZeneca, Boehringer Ingelheim and Teva; and payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Novartis and Teva. P.J.B. declares no non-financial competing interests.